Hotstocked Newsletters

Promoted Companies

PROMOTION HISTORY
SORT BY:

DARA Biosciences, Inc. (DARA)

Total paid for Promotions this month: $0
E-mails this Month: 2
Estimated Volume Generated: $0
Research Report on DARA: Click to see
* The information presented is based on information for Jun , 2014
Its Experimental Compound Gets FDA Orphan Drug Designation for Treatment of Multiple Myeloma (Mailing list information, including unsubscription instructions, is located at the end of this message.)   DARA BioSciences, Inc. (DARA)   Multiple myeloma is a cancer formed by malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.   Multiple myeloma is the second most common ...read more
Promoter: penny to buck Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
DARA Unknown compensation UNKNOWN
Max Profit: 13.43 % Gain at close: -4.48 %
Its Experimental Compound Gets FDA Orphan Drug Designation for Treatment of Multiple Myeloma (Mailing list information, including unsubscription instructions, is located at the end of this message.)   DARA BioSciences, Inc. (DARA)   Multiple myeloma is a cancer formed by malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.   Multiple myeloma is the second most common ...read more
Promoter: Double in stocks Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
DARA Unknown compensation UNKNOWN
Max Profit: 13.43 % Gain at close: -4.48 %
    SLXP, Salix Pharmaceuticals, Ltd.   ** On its third quarter fiscal 2011 results, SLXP posted total product revenue of $146.2 million, an 81% increase year over year.   SLXP is increasing its estimate of 2011 total product revenue to approximately $535 million, which represents 59% growth over 2010 revenue.   SLXP develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal ...read more
Promoter: penny to buck Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
DARA Unknown compensation UNKNOWN
Max Profit: 0.00 % Gain at close: -22.29 %
      SLXP, Salix Pharmaceuticals, Ltd.   ** On its third quarter fiscal 2011 results, SLXP posted total product revenue of $146.2 million, an 81% increase year over year.   SLXP is increasing its estimate of 2011 total product revenue to approximately $535 million, which represents 59% growth over 2010 revenue.   SLXP develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal ...read more
Promoter: Crweselect.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
DARA Unknown compensation UNKNOWN
Max Profit: 0.00 % Gain at close: -22.29 %
      SLXP, Salix Pharmaceuticals, Ltd.   ** On its third quarter fiscal 2011 results, SLXP posted total product revenue of $146.2 million, an 81% increase year over year.   SLXP is increasing its estimate of 2011 total product revenue to approximately $535 million, which represents 59% growth over 2010 revenue.   SLXP develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal ...read more
Promoter: Double in stocks Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
DARA Unknown compensation UNKNOWN
Max Profit: 0.00 % Gain at close: -22.29 %
      SLXP, Salix Pharmaceuticals, Ltd.   ** On its third quarter fiscal 2011 results, SLXP posted total product revenue of $146.2 million, an 81% increase year over year.   SLXP is increasing its estimate of 2011 total product revenue to approximately $535 million, which represents 59% growth over 2010 revenue.   SLXP develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal ...read more
Promoter: Stock-pr Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
DARA Unknown compensation UNKNOWN
Max Profit: 0.00 % Gain at close: -22.29 %
  ICLK, interCLICK, Inc.   ** Yahoo! Inc. reported a definitive agreement to acquire ICLK.   Under the terms of the agreement, Yahoo! will commence an all cash tender offer for all outstanding shares of common stock of ICLK at $9.00 per share. The transaction has an estimated total equity value of approximately $270 million.   Powered by OSM, ICLK offers proprietary data-valuation capabilities combining analytical expertise ...read more
Promoter: pennyomega.com Paying Party: No Third Party
Stocks covered: Compensation: Avg $ Volume for Period:
DARA No compensation UNKNOWN
Max Profit: 0.59 % Gain at close: -1.76 %
      ICLK, interCLICK, Inc.   ** Yahoo! Inc. reported a definitive agreement to acquire ICLK.   Under the terms of the agreement, Yahoo! will commence an all cash tender offer for all outstanding shares of common stock of ICLK at $9.00 per share. The transaction has an estimated total equity value of approximately $270 million.   Powered by OSM, ICLK offers proprietary data-valuation capabilities combining analytical ...read more
Promoter: penny to buck Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
DARA Unknown compensation UNKNOWN
Max Profit: 0.00 % Gain at close: -22.29 %
    ICLK, interCLICK, Inc.   ** Yahoo! Inc. reported a definitive agreement to acquire ICLK.   Under the terms of the agreement, Yahoo! will commence an all cash tender offer for all outstanding shares of common stock of ICLK at $9.00 per share. The transaction has an estimated total equity value of approximately $270 million.   Powered by OSM, ICLK offers proprietary data-valuation capabilities combining analytical expertise ...read more
Promoter: Stock-pr Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
DARA Unknown compensation UNKNOWN
Max Profit: 0.00 % Gain at close: -22.29 %
      ICLK, interCLICK, Inc.   ** Yahoo! Inc. reported a definitive agreement to acquire ICLK.   Under the terms of the agreement, Yahoo! will commence an all cash tender offer for all outstanding shares of common stock of ICLK at $9.00 per share. The transaction has an estimated total equity value of approximately $270 million.   Powered by OSM, ICLK offers proprietary data-valuation capabilities combining analytical ...read more
Promoter: Crweselect.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
DARA Unknown compensation UNKNOWN
Max Profit: 0.00 % Gain at close: -22.29 %
First  >> Last